Updated: One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial

Amber Tong

Arcutis Biotherapeutics is on a roll. Months after launching its topical formulation of an old AstraZeneca drug in plaque psoriasis, the company is touting positive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

Up­dat­ed: One down, one to go: Ar­cutis' re­pur­posed As­traZeneca drug clears first PhI­II eczema tri­al

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: One down, one to go: Arcutis' repurposed AstraZeneca drug clears first PhIII eczema trial